ALEC250117C12500
- 1.00
- 0.000.00%
Alector Newsroom
What You Need To Know About The Alector, Inc. (NASDAQ:ALEC) Analyst Downgrade Today
Alector Downgraded to Neutral From Outperform at Mizuho
Mizuho Securities Downgrades Alector(ALEC.US) to Hold Rating, Announces Target Price $2.5
Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15
Alector Price Target Announced at $4.00/Share by Stifel
Stifel Downgrades Alector(ALEC.US) to Hold Rating, Cuts Target Price to $4
Express News | Ra Capital Management, L.p. Reports 9.9% Passive Stake in Alector Inc as of Nov 29 - SEC Filing
BofA Securities Downgrades Alector(ALEC.US) to Sell Rating, Cuts Target Price to $1
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Express News | Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
BofA Securities Downgrades Alector to Underperform
Insider Sale: Chief Financial Officer of $ALEC (ALEC) Sells 16,489 Shares
A Quick Look at Today's Ratings for Alector(ALEC.US), With a Forecast Between $3 to $7
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Poseida PSTX Merger With RHHBY; Alector ALEC Phase 2 Fails
Alector Is Maintained at Buy by BTIG
Morgan Stanley Downgrades Alector to Underweight, Lowers Price Target to $3
Express News | Cantor Fitzgerald Reiterates Overweight on Alector
Alector Analyst Ratings